KCAS Expands Its Transatlantic Presence with the Acquisition of France-based Active Biomarkers
KCAS Bioanalytical and Biomarker Services (KCAS), a leading bioanalytical contract research organization (CRO), backed by Vitruvian Partners, closed the purchase of Active Biomarkers, located in Lyon, France. Active Biomarkers is a renowned assay development and specialty bioanalytical laboratory with expertise in oncology, infectious disease, inflammation and neurodegenerative disorders. Financial terms were not disclosed. Formerly owned by its management team and Turenne Santé fund, Active Biomarkers operates in a new, state-of-the-art facility in Lyon, France with significant expansion opportunities. This transaction adds valuable bioassay and cellular analysis expertise as well as European capacity to support customers globally as KCAS continues to advance its mission of providing high quality bioassay services to the biotech and pharmaceutical industries. The acquisition of Active Biomarkers is the second in 2022 by KCAS. FlowMetric, a leading flow cytometry and cellular analysis CRO, joined KCAS in early 2022. The Lyon site adds to KCAS and FlowMetric’s existing facilities in Kansas, Philadelphia and Milan, Italy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220912005063/en/
Active Biomarkers building in Lyon, France (Photo: Business Wire)
John Bucksath, CEO of KCAS, stated “We are delighted to partner with the Active Biomarkers team, accelerating our combined offering to support the customers we serve globally. The combined expertise and capacity of KCAS, FlowMetric, and Active Biomarkers is unique. The high-quality, science-first and client-centric culture we all share is key to our commitment to become the CRO partner of choice for the global pharma and biopharma industries. KCAS has embarked on significant investments, including a purpose-built 70,000 sq. ft. facility in Kansas City and a 26,000 sq. ft. facility in Pennsylvania, and accelerating our international footprint through acquisitions. We continue to attract the industry’s top scientific talent and focus on outstanding science and customer service. With our investors, Vitruvian Partners, we are optimally positioned to invest in our people and deliver world-class services for our growing client base. The acquisition of Active Biomarkers gives our combined clients access to further scientific expertise and support in both markets regionally and internationally.”
Marc Essodaigui, CEO of Active Biomarkers, comments, “Our entire team is thrilled about the new partnership with KCAS and the combined organizations’ outlook. This combination will allow us to provide even more comprehensive, best-in-class services for the biopharma and life sciences sector. The KCAS’ alliance, backed by a leading world-class growth investor, will provide us with the support and growth to expand our technological expertise, capacity, and geographical footprint.”
Sophie Bower-Straziota, Partner at Vitruvian Partners, comments, “Active Biomarkers has built a strong reputation in Europe founded in scientific excellence. The company fits with our investment strategy of backing best-in-class operations offering services to a market with strong tailwinds and internationalization opportunities. The acquisition of Active Biomarkers by KCAS builds on the excellent foundation KCAS has built in the US and supports the increasingly international needs of the company’s growing pharmaceutical and biotech clients. As the drug development market continues to evolve, we will continue to support investment in scientific capabilities, broadening geographical reach, providing the resources to scale the business, and making strategic acquisitions.”
About KCAS - KCAS is a rapidly growing company that provides comprehensive GLP compliant development services from early discovery support through product registration and beyond. One of only a select few CROs offering both large and small molecule development with extensive capabilities and expertise, KCAS provides a truly differentiated approach to its clients who are looking for both scientific expertise and excellent customer service. KCAS is headquartered in Olathe, Kansas – the Kansas City metro area and employs more than 300 employees. Website: KCASBio.com.
About Active Biomarkers – Founded in 2011, Active Biomarkers is an integrated bioanalytical laboratory offering a wide range of services, including PK, immunogenicity, soluble and cellular biomarker analyses for clinical studies. Operating in state-of-the-art BSL2 facilities, GCLP accredited and ISO 9001:2015 certified, the company has a unique track-record in the development, validation, and implementation of analytical methods. Its expert team has supported hundreds of studies in multiple therapeutic areas: oncology, infectious diseases, inflammatory pathologies, and neurodegenerative diseases. Beyond its state-of the-art flow cytometry and ELISpot capabilities, Active Biomarkers offers the broadest panel of immunoassay technologies in Europe, ranging from standard ELISA to multiplexed methods such as Luminex, SP-X or ELLA systems, or ultra-sensitive technologies such as MSD, Gyrolab or Simoa HD-X platforms. Website: active-biomarkers.com
About Vitruvian - Vitruvian is a leading international growth investor headquartered in London with additional offices in Stockholm, Madrid, Munich, Luxembourg, San Francisco, Singapore and Shanghai. Vitruvian focuses on dynamic situations characterized by rapid growth and change across industries. Vitruvian has backed over 90 companies and has assets under management of approximately €10 billion. Website: vitruvianpartners.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005063/en/
Contact information
KCAS Bioanalytical and Biomarker Services
Tonya Masters, (913) 248-3000
Pressrelease@KCASBio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Parse Biosciences and Codebreaker Labs Partner to Apply Whole Transcriptome Single Cell Profiling and Causal Genomics at Scale19.12.2025 15:00:00 EET | Press release
Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced a collaboration with Codebreaker Labs to develop and validate a breakthrough platform capable of testing thousands of genetic variants in parallel and measuring their effects at single cell resolution. By combining Codebreaker’s synthetic biology platform and variant engineering capabilities with the scale and accessibility of Parse’s Evercode™ technology, the collaboration aims to generate the causal data increasingly sought by AI developers, drug discovery teams, and clinical researchers. Today’s genomic studies rely heavily on observational data, or variants that appear in large populations. But rare and private variants, often only seen in one individual or family, are nearly impossible to study this way because too few carriers of the variant exist to draw statistically meaningful conclusions. As a result, even the most advanced models trained on observational datas
Cyviz Awarded Two Classified NATO Defense Contracts19.12.2025 09:00:00 EET | Press release
Norwegian technology and platform company Cyviz AS has been awarded two classified defense contracts by major European NATO-partner nations to deliver a fully mobile, containerised Command & Control (C2) capability, strengthening Europe’s operational readiness in high-threat and expeditionary environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218625485/en/ Image from a previous military exercise where Cyviz demonstrated a mobile command center solution. The contracts cover the design, integration, and delivery of secure, deployable operations centres engineered to NATO security standards, enabling military and security forces to establish full theatre-class command capability wherever operations require. Due to the sensitive nature of the missions, contract value and customer identities remain undisclosed. From Demonstrated Readiness to Operational Deployment The awards follow growing interest among European def
S3NS Announces SecNumCloud Qualification for PREMI3NS, its Trusted Cloud Offering19.12.2025 08:00:00 EET | Press release
S3NS, a subsidiary of Thales in partnership with Google Cloud, today announced that PREMI3NS, its "Trusted Cloud" (Cloud de confiance) offering, has received the SecNumCloud 3.2 qualification delivered by the French National Agency for the Security of Information Systems (ANSSI). Meeting SecNumCloud 3.2’s protection and resilience requirements, which are known as the most demanding ones in France and Europe, it offers immunity from non-European extraterritorial laws. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218817208/en/ ANSSI delivered the SecNumCloud 3.2 qualification for S3NS’ PREMI3NS offering, meeting all its requirements and passing all three milestones of the qualification process. With PREMI3NS, S3NS now offers businesses and public sector organizations the most extensive cloud service among the offerings that have received the SecNumCloud 3.2 qualification. PREMI3NS integrates the most advanced IaaS and Paa
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 03:00:00 EET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn
Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 01:34:00 EET | Press release
Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of the EIOS:VSE stock reflects this strength: Price per Share (PPS): +132% in the first half (H1) of 2025, stabilizing at a +116% YTD increase. Daily Trading Volume: peaks of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom